- Home
- MIST vs CTOR Comparison
MIST vs CTOR Comparison
Compare MIST & CTOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIST
- CTOR
- Stock Information
- Founded
- MIST 2003
- CTOR 2021
- Country
- MIST Canada
- CTOR United States
- Employees
- MIST N/A
- CTOR N/A
- Industry
- MIST Biotechnology: Pharmaceutical Preparations
- CTOR
- Sector
- MIST Health Care
- CTOR
- Exchange
- MIST Nasdaq
- CTOR NYSE
- Market Cap
- MIST 53.9M
- CTOR 52.2M
- IPO Year
- MIST N/A
- CTOR N/A
- Fundamental
- Price
- MIST $1.11
- CTOR $0.87
- Analyst Decision
- MIST Strong Buy
- CTOR Strong Buy
- Analyst Count
- MIST 2
- CTOR 2
- Target Price
- MIST $9.50
- CTOR $4.50
- AVG Volume (30 Days)
- MIST 1.6M
- CTOR 66.6K
- Earning Date
- MIST 05-20-2025
- CTOR 05-21-2025
- Dividend Yield
- MIST N/A
- CTOR N/A
- EPS Growth
- MIST N/A
- CTOR N/A
- EPS
- MIST N/A
- CTOR N/A
- Revenue
- MIST N/A
- CTOR N/A
- Revenue This Year
- MIST N/A
- CTOR N/A
- Revenue Next Year
- MIST N/A
- CTOR N/A
- P/E Ratio
- MIST N/A
- CTOR N/A
- Revenue Growth
- MIST N/A
- CTOR N/A
- 52 Week Low
- MIST $0.63
- CTOR $0.55
- 52 Week High
- MIST $2.75
- CTOR $49.00
- Technical
- Relative Strength Index (RSI)
- MIST 43.96
- CTOR N/A
- Support Level
- MIST $1.28
- CTOR N/A
- Resistance Level
- MIST $1.32
- CTOR N/A
- Average True Range (ATR)
- MIST 0.12
- CTOR 0.00
- MACD
- MIST 0.02
- CTOR 0.00
- Stochastic Oscillator
- MIST 27.39
- CTOR 0.00
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
About CTOR CITIUS ONCOLOGY INC
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.